Wegovy vs. Zepbound: Head-to-Head Weight Loss Drug Study Results

New Study Compares Wegovy and Zepbound

• 💡 A recent head-to-head clinical trial compared Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss.
• 🎯 The study, funded by Eli Lilly (maker of Zepbound), found that tirzepatide led to significantly greater weight loss.
• ⚠️ Participants in the study had a certain BMI but did not have diabetes, indicating use for off-label weight loss purposes.

Weight Loss Outcomes

• 📊 Participants taking Zepbound lost an average of 50 pounds (20% of body weight) over 72 weeks.
• 📈 Those taking Wegovy lost an average of 33 pounds (14% of body weight) over the same period.
• 🚀 This represents over 50% more weight loss for Zepbound users compared to Wegovy users.

Additional Health Benefits

• ❤️ Beyond weight loss, users of both drugs experienced benefits like reduced blood pressure, improved blood fat levels, and lower blood sugar.
• 📏 A smaller waistline was observed, which is a key indicator for heart disease risk.
• 🩺 Health experts note that while Zepbound showed accelerated results, both drugs can benefit people in different ways.

Broader Applications of GLP-1 Drugs

• 🧩 GLP-1 drugs are being explored for a variety of other ailments, including arthritis (due to inflammation reduction) and liver disease.
• 🧠 Some studies suggest potential benefits for cognitive decline, with links to Alzheimer's and type 3 diabetes.
• 🤝 These drugs are also being investigated for use in treating addiction.
• ⚠️ It's important to note that these treatments are still fairly expensive, especially without a prescription.